InflaRx Regains Nasdaq Listing Compliance, Avoiding Delisting Risk

Key Facts

Biopharmaceutical company InflaRx has officially regained compliance with Nasdaq's minimum bid price requirement, resolving the immediate threat of delisting. The company achieved this milestone after its common stock maintained a closing bid price of at least $1.00 per share for ten consecutive business days. By meeting the standards of Nasdaq Listing Rule 5450(a)(1), InflaRx has successfully closed the compliance matter with the exchange. This development is crucial for maintaining the stock's liquidity and ensuring continued access to public capital markets. While the news represents a regulatory correction rather than a fundamental shift in operations, it removes a significant overhang for shareholders. Analysts view this as a positive step that stabilizes the company's market position as it continues its clinical development programs.